ArticleFrontiers in aging neuroscience2026
The inflammation-fibrosis combined index as a predictor of prognosis in stroke patients undergoing mechanical thrombectomy.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: This study evaluates the novel Inflammation-Fibrosis Combined Index (IFCI) for predicting 90-day functional outcomes post-MT. Methods: We conducted a retrospective analysis of 548 consecutive acute ischemic stroke patients treated with MT. The IFCI was derived from the combination of the Fibrosis-4 (FIB-4) index and the systemic immune-inflammation index (SII). The primary outcome was an unfavorable functional outcome (modified Rankin Scale score 3-6) at 90 days. The association between IFCI and the outcome was assessed using multivariable logistic regression and restricted cubic splines. Results: Among the 548 patients (mean age 70.6 years, 56.2% male), 275 (50.2%) experienced an unfavorable outcome. In multivariable analysis, each 1-point increase in IFCI was independently associated with a 2.51-fold increased odds ratio of poor outcome (95% confidence interval [CI], 1.69-3.73; Conclusions: By integrating the marker of inflammation and fibrosis pathways, the IFCI is an independent predictor of 90-day outcome after MT. It provides prognostic value beyond conventional variables and its individual components, and may serve as a useful tool for early risk assessment and patient management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.